PuSH - Publication Server of Helmholtz Zentrum München: Comparison of premixed human insulin 30/70 to biphasic aspart 30 in well-controlled patients with type 2 diabetes using continuous glucose monitoring.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Margaritidis, C.* ; Karlafti, E.* ; Kotzakioulafi, E.* ; Kantartzis, K. ; Tziomalos, K.* ; Kaiafa, G.* ; Savopoulos, C.* ; Didangelos, T.*

Comparison of premixed human insulin 30/70 to biphasic aspart 30 in well-controlled patients with type 2 diabetes using continuous glucose monitoring.

J. Clin. Med. 10:1982 (2021)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Aim: To compare in terms of glycemic variability two premixed insulins, Premixed Human Insulin 30/70 (PHI) and Biphasic Aspart 30 (BiAsp30), using Continuous Glucose Monitoring (CGM) and to estimate the correlation of Glycated Albumin (GA) and Fructosamine (FA) with CGM data. Patients-Data: A total of 36 well-controlled patients with type 2 Diabetes Mellitus (T2DM) underwent 7-day CGM with PHI and subsequently with BiAsp30. GA and FA were measured at the first and last day of each week of CGM. Results: BiAsp30 was associated with lower Average Blood Glucose (ABG) during the 23:00-03:00 period (PHI: 135.08 +/- 28.94 mg/dL, BiAsp30: 117.75 +/- 21.24 mg/dL, p < 0.001) and the 00:00-06:00 period (PHI: 120.42 +/- 23.13 mg/dL, BiAsp30: 111.17 +/- 14.74 mg/dL, p = 0.008), as well as with more time below range (<70 mg/dL) (TBR) during the 23:00-03:00 period in the week (PHI: 3.65 +/- 5.93%, BiAsp30: 11.12 +/- 16.07%, p = 0.005). PHI was associated with lower ABG before breakfast (PHI: 111.75 +/- 23.9 mg/dL, BiAsp30: 128.25 +/- 35.9 mg/dL, p = 0.013). There were no differences between the two groups in ABG, Time In Range and Time Below Range during the entire 24-h period for 7 days, p = 0.502, p = 0.534, and p = 0.258 respectively, and in TBR for the 00:00-06:00 period p = 0.253. Total daily insulin requirements were higher for BiAsp30 (PHI: 47.92 +/- 12.18 IU, BiAsp30: 49.58 +/- 14.12 IU, p = 0.001). GA and FA correlated significantly with ABG (GA: r = 0.512, p = 0.011, FA: r = 0.555, p = 0.005). Conclusions: In well-controlled patients with T2DM, BiAsp30 is an equally effective alternative to PHI.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

4.241

0.000